Main Article Content
Serotonin, Ceruloplasmin, Copper, CEA, CA15-3, Breast cancer
Background: The serotonin, copper, and ceruloplasmin markers are altered in various cancers, including breast cancer. It has been reported that these markers have the potential to be used in the study of cancer recurrence. The purpose of this study was to compare the levels of serotonin, copper and ceruloplasmin besides the routine breast cancer markers such as CEA and CA15-3 in the blood sample of patients with invasive ductal breast cancer, before and after chemotherapy.
Methods: This study was performed on 30 patients with breast cancer. Blood samples were taken from the patients before and after chemotherapy. Necessary data including age, tumor grade and status of Her-2, ER, PR receptors were obtained from patient records. Serotonin, CEA and CA15-3 levels were measured by ELISA method. Ceruloplasmin and copper were measured by nephelometry and colorimetric methods, respectively.
Results: Results showed a decrease in serotonin, ceruloplasmin, copper, CEA and CA15-3 after treatment but only the levels of serotonin and ceruloplasmin showed a steady decrease. No significant relationship was observed between tumor grade and ER-PR, Her-2 receptors.
Conclusion: This study showed that chemotherapy resulted in steady decline in serotonin and ceruloplasmin levels but this decrease was not steady in levels of CA15-3 and CEA. Therefore, if our results are confirmed by further research, they can be considered as a viable alternative to routine markers in cancer recurrence after chemotherapy.
2. Selz J, Stevens D, Jouanneau L, Labib A, Le Scodan R. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2012;84(5):1123-32.
3. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up. Histopathology. 1991;19(5):403-10.
4. Sardareh HM, Goodarzi MT, Yadegar-Azari R, Poorolajal J, Mousavi-Bahar SH, et al. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals. Urol J. 2014;11(06):1952-8.
5. Lee J, Park S, Park J, Cho J, Kim S, et al. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol. 2012;24(5):1225-31.
6. Molina R, Auge JM, Farrus B, Zanón G, Pahisa J, et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem. 2010;56(7):1148-57.
7. Samy N, Ragab HM, Maksoud E, Abd N, Shaalan M. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomark. 2010;6(2):63-72.
8. Wu S-g, He Z-y, Zhou J, Sun J-y, Li F-y, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014;23(1):88-93.
9. Siddiqui EJ, Thompson CS, Mikhailidis DP, Mumtaz FH. The role of serotonin in tumour growth. Oncol Rep. 2005;14(6):1593-7.
10. Pai VP, Marshall AM, Hernandez LL, Buckley AR, Horseman ND. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res. 2009;11(6):R81.
11. Juhász C, Nahleh Z, Zitron I, Chugani DC, Janabi MZ, et al. Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies. Nucl Med Biol. 2012;39(7):926-32.
12. Fröbe A, Čičin-Šain L, Jones G, SOLDIĆ Ž, Lukač J, et al. Plasma free serotonin as a marker for early detection of breast cancer recurrence. Anticancer Res. 2014;34(3):1167-9.
13. Xia Y, Wang D, Zhang N, Wang Z, Pang L. Plasma serotonin level is a predictor for recurrence and poor prognosis in colorectal cancer patients. J Clin Lab Anal. 2018;32(2):e22263.
14. Podolsky DK. Derangements of hepatic metabolism. Harrison's principles of internal medicine. 1998:1311-7.
15. Hrgovcic M, Tessmer CF, Thomas FB, Ong PS, Gamble J, et al. Serum copper observations in patients with malignant lymphoma. Cancer. 1973;32(6):1512-24.
16. Sinha SN, Gabrieli ER. Serum copper and zinc levels in various pathologic conditions. Am J Clin Pathol. 1970;54(4):570-7.
17. Kunapuli SP, Singh H, Singh P, Kumar A. Ceruloplasmin gene expression in human cancer cells. Life Sci. 1987;40(23):2225-8.
18. Ebrahimifar M, Nili-Ahmadabadi A, Akbarzadeh A, Shahemabadi HE, Hasanzadegan M, et al. Preparation, characterization and cytotoxic effects of pegylated nanoliposomal containing carboplatin on ovarian cancer cell lines. Indian J Clin Biochem. 2017;32(2):230-4.
19. Sajjadiyan SZ, Ghadernejad H, Milani AT, Mohammadian M, Abdolahpour S, et al. Preparation of silibinin loaded pegylatedniosomal nanoparticles and investigation of its effect on MCF-10A human breast cancer cell line. Pharm Lett. 2016;8(16):70-5.
20. Fu Y, Li H. Assessing clinical significance of serum CA15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: a meta-analysis. Med Sci Mon Int Med J Exp Clin Res. 2016;22:3154.
21. Agrawal A, Jelen M, Rudnicki J, Grzebieniak Z, Zyśko D, et al. The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type. Folia Histochem Cytobiol. 2010;48(1):26-9.
22. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006;52(3):345-51.
23. Mirabelli P, Incoronato M. Usefulness of traditional serum biomarkers for management of breast cancer patients. Biomed Res Int. 2013;2013.
24. Shooshtary MHS, Talaizadeh A, Assar S, Arnineh BK, Nateghi J, et al. Evaluation of carcinoemberionic antigen CEA and CA15. 3 tumor markers in patients operated for breast cancer. Pak J Med Sci. 2007;23(1):115-8.
25. Gordon RR, Wu M, Huang C-Y, Harris WP, Sim HG, et al. Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. PLoS One. 2014;9(9):e104271.
26. O'Hanlon DM, Lynch J, Cormican M, Given HF. The acute phase response in breast carcinoma. Anticancer Res. 2002;22(2B):1289-93.
27. Shenkin A. Trace elements and inflammatory response: implications for nutritional support. Nutrition (Burbank, Los Angeles County, Calif). 1995;11(1 Suppl):100-5.
28. Schapira DV, Schapira M. Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer. Breast Cancer Res Treat. 1983;3(2):221-4.
29. Vaidya S, Kamalakar P. Copper and ceruloplasmin levels in serum of women with breast cancer. Indian J Med Sci. 1998;52(5):184-7.
Article Statistics :Views : 290 | Downloads : 196 : 56